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Abstract
Background The results from a phase III trial conducted
outside of Japan demonstrated a significant improvement in
time to progression (TTP) when lapatinib was combined
with capecitabine compared with capecitabine alone in
patients with HER2-positive advanced or metastatic breast
cancer. In this clinical study of lapatinib in combination
with capecitabine, efficacy, safety, pharmacokinetics (PK)
and biomarkers were investigated in Japanese patients with
HER2-positive advanced or metastatic breast cancer trea-
ted with prior trastuzumab.
Methods Eligible women received lapatinib 1250 mg
once daily and capecitabine 1000 mg/m2 twice daily on
days 1 through 14 of a 21-day cycle. The primary endpoint
was the clinical benefit rate (CBR: complete response,
partial response or stable disease for at least 24 weeks).
Results Lapatinib in combination with capecitabine was
well tolerated in the 51 patients enrolled in this study. CBR
was 59 % (95 % CI 44.2, 72.4), and the median TTP in the
Kaplan-Meier estimate was 36 weeks (95 % CI 27.1, 48.0).
The majority of drug-related adverse events were mild to
moderate (grade 1 or 2); the most common adverse events
reported were palmar-plantar erythrodysesthesia syndrome
(76 %), diarrhea (67 %) and stomatitis (41 %).
Conclusions Lapatinib in combination with capecitabine
in Japanese HER2-positive breast cancer patients was well
tolerated. Overall, our findings on the efficacy, safety and
PK were similar to those reported from the overseas studies.
Keywords Lapatinib  Capecitabine  HER2  Breast
cancer  Biomarker
Introduction
Approximately 20 % of breast cancers exhibit overex-
pression or gene amplification of human epidermal growth
factor receptor 2 (HER2), which is known to be associated
with aggressive disease and a greater risk of disease pro-
gression and death [1].
Lapatinib is a reversible, bioavailable and small molecule
tyrosine kinase inhibitor (TKI) that potently inhibits both
epidermal growth factor receptor (EGFR) and HER2. EGF
receptor family TKIs, such as lapatinib, compete intracel-
lularly with adenosine triphosphate for its receptor binding
site and inhibit the tyrosine kinase activity of the receptor. In
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principle, small molecule TKIs should inhibit the activity of
EGF receptors in the presence of elevated levels of ligand as
well as the activity of EGF receptors with truncated extra-
cellular domains (ECDs). In fact, single agent small mole-
cule TKIs have been reported to exhibit clinical activity [2].
A randomized, overseas phase III study evaluating the
efficacy and safety of lapatinib in combination with capecit-
abine in women with HER2-positive advanced or metastatic
breast cancer (MBC) that progressed following prior therapy
including trastuzumab provided the evidence of the efficacy
and safety for this combination [3–5]. Further studies evalu-
ating lapatinib and capecitabine have been reported in the past
[6–9]; however, these studies were not conducted in Japan.
We now report the findings from a clinical study of the safety,
efficacy, pharmacokinetics (PK) and biomarkers in Japanese
patients with HER2-positive advanced or MBC treated with
lapatinib in combination with capecitabine.
Patients and methods
Study design
This was an open-label, multicenter study. The objectives
of this study were to evaluate the safety, tolerability, PK
and efficacy as determined by the clinical benefit rate
[CBR: complete response (CR), partial response (PR) or
stable disease (SD) for at least 24 weeks] of lapatinib in
combination with capecitabine at the overseas recom-
mended dosage (i.e., lapatinib 1250 mg/day QD and
capecitabine 2000 mg/m2/day BID) in Japanese patients
with HER2-positive advanced or MBC. Secondary end-
points were time to progression (TTP: the interval between
the start of treatment and the earliest date of disease pro-
gression or death due to breast cancer, whichever is
sooner), progression-free survival (PFS), 6-month pro-
gression-free survival, overall response rate [ORR: the
percentage of subjects achieving best overall response
classified as CR or PR (confirmed)], overall survival (OS),
time to response, duration of response, PK parameters and
adverse events (throughout the study period).
The study consisted of two parts; the first part (part 1)
was to determine the safety, tolerability and PK parameters
of lapatinib given with capecitabine in the six patients
enrolled. This was done as it was the first time Japanese
patients had received lapatinib in combination with cape-
citabine. If no major safety concerns were observed in part
1, the study moved into the second part (part 2) to further
evaluate safety as well as efficacy and biomarkers.
The tolerability criteria in part 1 were defined as grade 3
or 4 drug-related non-hematological toxicity (exclud-
ing C grade 3 diarrhea, nausea or vomiting); grade 3 or 4
drug-related diarrhea, nausea or vomiting in the presence of
supportive care; hematological toxicity (grade 4 drug-
related neutropenia lasting C 5 days, febrile neutrope-
nia C grade 3 or thrombocytopenia B 25000/mm3);
inability to start the next treatment cycle due to unresolved
toxicity; missing [ 50 % of scheduled doses in a cycle due
to toxicity. If two or fewer subjects in the six subjects
experienced a safety issue corresponding with the tolera-
bility criteria, the study medication was concluded to be the
tolerable regimen. The study was conducted in accordance
with Good Clinical Practice guidelines and the Declaration
of Helsinki.
Patient eligibility
Eligible patients were women aged 20 years or older with
histologically confirmed invasive and advanced or metastatic
(stage IIIB, stage IIIC with T4 lesion or stage IV) breast cancer
that was HER2-positive [confirmed immunohistochemistry
(IHC) 3 ? or IHC 2 ?/fluorescence in situ hybridization
(FISH) positive] by a local laboratory. Patients were required
to have measurable lesion(s) according to the Response
Evaluation Criteria in Solid Tumors (RECIST) version 1.0
[10]. Patients must have received prior therapy including
anthracyclines, taxanes and trastuzumab. Additional inclusion
criteria were Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1, life expectancy of at least
12 weeks, left ventricular ejection fraction (LVEF) within the
institutional normal range (or C 50 %), adequate renal,
hepatic and hematologic functions, and archived tumor tissue
available for biomarker analysis. Patients were excluded if
they had had prior therapy with capecitabine or an EGFR and/
or HER2 inhibitor other than trastuzumab, or if they had
malabsorption syndrome or other conditions that would pre-
vent the efficacy and safety evaluation of study regimen. All
patients signed an informed consent.
Treatment schedule
Lapatinib 1250 mg was taken orally once daily at
approximately the same time every day. Capecitabine was
taken orally twice daily (needed 12-h of administration
interval) for 14 days in every 21 days. Each dose of
capecitabine was 1000 mg/m2. Subjects were treated until
disease progression or unacceptable toxicity.
Safety and efficacy assessments
Safety assessment was performed every week for the first
3 weeks, every 6 weeks from week 3 to week 24, then every
12 weeks and at the end of treatment. Adverse events were
checked and laboratory tests were performed in all subjects
every 3 weeks. LVEF assessment by echocardiogram and
efficacy assessments were performed every 6 weeks for
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24 weeks, then every 12 weeks and at the end of treatment.
Subjects withdrawn from the study without disease pro-
gression were assessed every 12 weeks until progression,
start of post anticancer therapy or death. Adverse events were
assessed according to the National Cancer Institute Common
Terminology Criteria for Adverse Events (CTCAE version
3.0). Efficacy was assessed by the independent review using
images or photographic data, in accordance with the RE-
CIST. During the study treatment, investigators reviewed
tumor response for timely evaluations.
PK assessment
PK assessment was performed in six subjects enrolled into
part 1: blood samples were obtained on day 14 for over
24-h period. Blood samples [2 ml was collected in ethy-
lenediaminetetraacetic acid (EDTA) tubes] for the analysis
of lapatinib were drawn before dosing and 1, 2, 3, 4, 6, 8,
10, 12 and 24 h after dosing of lapatinib. Blood samples
(4 ml, collection in EDTA tubes) for the analysis of
capecitabine, 5-fluorouracil (5-FU) and a-fluoro-b-alanine
(FBAL) were drawn before dosing and 0.5, 1, 2, 3, 4, 6, 8
and 10 h after the morning dose of capecitabine.
PK samples were also collected from the subjects
enrolled in part 2 to determine the plasma drug concen-
trations on day 14 and day 21: blood samples (2 ml for
lapatinib and 6 ml for capecitabine, 5-FU and FBAL) were
taken at two time points: before lapatinib and the morning
dose of capecitabine on day 14 (for assay of lapatinib,
capecitabine, 5-FU and FBAL) and before dosing of la-
patinib on day 21 (for assay of lapatinib). Blood plasma
was cold centrifuged at about 1000 9 g for 10–15 min,
and the plasma gained was stored at -20 C or lower.
PK parameters were calculated using WinNonlin Pro-
fessional version 4.1. In part 1, maximum plasma con-
centration (Cmax), time to Cmax (tmax), terminal elimination
half-life (t1/2), area under the plasma concentration–time
curve within the dosing interval (AUC0–s) and area under
the plasma concentration–time curve from 0 to 24 h
(AUC0–24) of lapatinib, Cmax, tmax, t1/2, AUC0–s and area
under the plasma concentration–time curve from 0 to 12 h
(AUC0–12) of capecitabine, 5-FU and FBAL were calcu-
lated as the PK parameters. In part 2 trough concentrations
of lapatinib, capecitabine, 5-FU and FBAL were measured.
Statistical analysis
This study was designed to perform no hypothesis testing.
A sample size was determined based on the study feasi-
bility. An intent-to-treat (ITT) population was used for
efficacy data analyses. For subjects who had withdrawn
from the study regimen without disease progression or
death, TTP was censored at the day of evaluation just
before initiating an alternative anticancer therapy. Version
9.2.3 Windows SAS System (SAS is a registered trade-
mark of the SAS Institute, Inc., Cary, NC, USA) was used
to analyze the data.
Biomarker assessments
Formalin-fixed, paraffin-embedded (FFPE) archived tumor
tissue blocks (or sections) from time of original diagnosis
or from recurrent/metastatic site were required for enroll-
ment. Intratumoral EGFR protein expression levels were
determined using the EGFR pharmDxTM assay (Dako).
Serum blood samples were collected at baseline for the
quantitative determination of serum HER2 ECD levels
using HER-2/neu enzyme-linked immunosorbent assay
(Wilex, Inc.).
HER2 ECD analyses applied a pre-specified cutoff value
of 15 ng/ml whereby subjects were grouped according to
whether HER2 ECD levels were elevated ([ 15 ng/ml) or
at the reference normal value of 15 ng/ml or below.
Additionally, subjects were grouped according to EGFR
IHC scores: IHC 0 was considered as EGFR negative and
IHC 1 ?/2 ?/3 ? considered as EGFR positive. TTP was
summarized using Kaplan-Meier curves and compared
between subgroups using a stratified log-rank test. For
CBR, HER2 ECD subgroups were compared using the
Wilcoxon rank sum test. Statistical tests with an alpha level
of 5 % were considered to indicate statistical significance.
Analyses were conducted using SAS version 9.1.3.
Results
Patient characteristics
During the period from June 2007 to September 2008, a
total of 51 patients were enrolled from 15 centers and
treated with the study regimen. As of the final data collec-
tion date, 46 subjects (90 %) had discontinued the treatment
because of disease progression and 5 (10 %) because of
adverse events. Overall, 36 deaths (71 %) were reported.
The majority of patients (80 %) had histologically
diagnosed invasive carcinoma NOS (Table 1). Most sub-
jects (71 %) had estrogen receptor (ER)-negative breast
cancer as assessed by a local laboratory. The majority of
patients had two or more metastatic sites at screening. All
patients had at least three prior anti-tumor regimens
including anthracyclines, taxanes and trastuzumab. Most
patients (78 %) had received their last trastuzumab treat-
ment less than 8 weeks prior to study enrollment.
The median duration of lapatinib treatment was
182 days and that of capecitabine was 128 days. The lon-
gest treatment period of lapatinib was 833 days.
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Tolerability and safety
In part 1, the safety and tolerability of study treatment were
assessed in six subjects. During two cycles when tolera-
bility was evaluated according to the protocol, all subjects
experienced drug-related adverse events, such as fatigue,
diarrhea and pruritus. All adverse events were grade 1 or 2
in severity with the exception of one case of a grade 3
neutrophil count decrease. This subject also experienced
grade 2 cystitis and a grade 2 white blood cell (WBC)
count decrease. None of the subjects were considered to
have met the tolerability criteria. Based on these findings,
the combination of lapatinib with capecitabine established
in earlier studies was also tolerable in Japanese MBC
patients.
A total of 51 subjects experienced at least one adverse
event regardless of the relationship with the study treat-
ments, and most of which were at grade 1 or 2. The most
common adverse events reported were palmar-plantar
erythrodysesthesia (PPE) syndrome, diarrhea and stomatitis
(Table 2). In addition, all subjects experienced drug-related
adverse events during the study periods. Grade 4 serious
adverse events reported were an alanine aminotransferase
increase, neutrophil count decrease, bone marrow failure
and pericardial effusion.
A total of two fatal serious adverse events (dysphagia
and respiratory failure) were reported in one subject and
determined to be unrelated to the study medication by the
investigator. Disease progression was considered to be the
major cause of death. Eight additional serious adverse
events were reported in seven subjects (14 %). These
included five treatment-related serious adverse events that
occurred in four subjects: grade 3 vertigo and grade 3
syncope were observed in one subject, grade 1 and 2 left
ventricular dysfunction were observed in one subject each,
and grade 2 pulmonary tuberculosis was observed in one
subject. Cardiac events, which are known to be a potential
risk of HER2 target agents including lapatinib and trast-
uzumab, occurred in three subjects (6 %). These subjects
experienced left ventricular dysfunction that was asymp-
tomatic and later resolved.
Pharmacokinetics
In part 1, following administration of lapatinib in combination
with capecitabine on day 14 (n = 5), tmax values were
approximately 3–6 h for lapatinib, 0.5–3 h for capecitabine,
approximately 2 h for 5-FU and approximately 3 h for FBAL
(Table 3). Co-administered lapatinib and capecitabine were
rapidly absorbed, and plasma concentrations of lapatinib,
capecitabine, 5-FU and FBAL showed rapid increases.
Plasma concentrations of lapatinib, capecitabine and 5-FU
Table 1 Baseline characteristics of ITT population
Age, years
Median (range) 55.0 (35-75)




Disease type, n (%)
Invasive carcinoma NOS 41 (80)
Papillary tubular carcinoma 9 (18)
Invasive lobular carcinoma 1 (2)



















Endocrine therapy 20 (39)
Vaccines 0
Immunotherapy 0
Duration from completion of trastuzumab, n (%) (weeks)
\8 40 (78)
C8 11 (22)




Visceral or nonvisceral metastatic, n (%)
Visceral 42 (82)
Nonvisceral 9 (18)
Hormone receptor status, n (%)
ER? and/or PgR? 15 (29)
ER? and PgR? 7 (14)
ER? and PgR- 8 (16)
ER- and PgR- 35 (69)
Unknown 1 (2)
ER estrogen receptor, PgR progesterone receptor
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reached Cmax and then decreased in a linear fashion. t1/2 values
of FBAL were just under 2.5 h, which was longer than that of
capecitabine and 5-FU by approximately three-fold.
In part 2, mean (standard deviation) pre-dose concen-
trations of lapatinib were 1.07 (0.72) lg/ml on day 14 and
1.24 (0.85) lg/ml on day 21. At pre-dose on day 14,
plasma concentrations of capecitabine were below the limit
of quantitation in most of the subjects, plasma concentra-
tions of 5-FU were below the limit of quantitation in all of
the subjects, and the mean (standard deviation) plasma
concentration of FBAL was 0.67 (0.46) lg/ml.
Efficacy
The primary endpoint of this study was CBR. Of 51
patients enrolled, 30 subjects (59 %) derived clinical ben-
efit (95 % CI 44.2, 72.4) (Table 4). ORR in the ITT pop-
ulation was 24 % (95 % CI 12.8, 37.5) with 12 PRs
(24 %), while SD and progressive disease (PD) were
Table 2 Summary of adverse
events experienced by at least




Adverse event, n (%) Grade 1 Grade 2 Grade 3 Grade 4 Total
PPE syndrome 18 (35) 16 (31) 5 (10) 0 39 (76)
Diarrhea 26 (51) 7 (14) 1 (2) 0 34 (67)
Stomatitis 21 (41) 0 0 0 21 (41)
Rash 13 (25) 6 (12) 1 (2) 0 20 (39)
Pruritus 16 (31) 1 (2) 0 0 17 (33)
Nausea 15 (29) 2 (4) 0 0 17 (33)
Fatigue 16 (31) 1 (2) 0 0 17 (33)
Anorexia 15 (29) 1 (2) 1 (2) 0 17 (33)
Blood bilirubin increased 6 (12) 10 (20) 0 0 16 (31)
Dry skin 13 (25) 1 (2) 1 (2) 0 15 (29)
Alanine aminotransferase increased 9 (18) 4 (8) 1 (2) 1 (2) 15 (29)
Aspartate aminotransferase increased 9 (18) 3 (6) 3 (6) 0 15 (29)
Nasopharyngitis 14 (27) 1 (2) 0 0 15 (29)
White blood cell count decreased 2 (4) 10 (20) 2 (4) 0 14 (27)
Paronychia 11 (22) 3 (6) 0 0 14 (27)
Neutrophil count decreased 3 (6) 4 (8) 3 (6) 1 (2) 11 (22)
Pigmentation disorder 9 (18) 0 0 0 9 (18)
Pyrexia 8 (16) 1 (2) 0 0 9 (18)
Blood alkaline phosphatase increased 7 (14) 0 1 (2) 0 8 (16)
Red blood cell count decreased 8 (16) 0 0 0 8 (16)
Cheilitis 7 (14) 0 0 0 7 (14)
Weight decreased 4 (8) 3 (6) 0 0 7 (14)
Headache 6 (12) 1 (2) 0 0 7 (14)
Skin exfoliation 6 (12) 1 (2) 0 0 7 (14)
Vomiting 4 (8) 2 (4) 0 0 6 (12)
Malaise 5 (10) 1 (2) 0 0 6 (12)
Dizziness 5 (10) 0 1 (2) 0 6 (12)
Cancer pain 3 (6) 3 (6) 0 0 6 (12)
Acne 3 (6) 1 (2) 1 (2) 0 5 (10)
Nail disorder 4 (8) 1 (2) 0 0 5 (10)
Constipation 5 (10) 0 0 0 5 (10)
Blood albumin decreased 3 (6) 2 (4) 0 0 5 (10)


































a Geometric mean (95 % confidence interval)
b Median (range)
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observed in 63 % (32/51) and 12 % (6/51), respectively;
one subject had an unknown response. The median TTP
was 36.0 weeks (95 % CI 27.1, 48.0) (Fig. 1). The median
OS was 78.6 weeks (95 % CI 51.6, 103.0).
Biomarker
All subjects enrolled were HER2-positive (IHC 3 ? or
FISH positive) by a local laboratory. Based on results of
the HER2 status assessed at the central laboratory, 4 % (2/
50) were IHC 0, 4 % (2/50) 1 ? , 32 % (16/50) 2 ? and
60 % (30/50) 3 ? ; 91 % (43/47) were FISH positive
(ratio C 2.0) and 9 % (4/47) were negative (ratio \ 2.0)
(Table 5). Three out of 47 subjects were evaluated as
HER2 negative by IHC and FISH, i.e. one subject was IHC
0/FISH negative, another was IHC 1 ?/FISH negative, and
the other was IHC 2 ?/FISH negative. There was one
subject whose tumor tissue was non-evaluable for HER2
testing.
Of 49 subjects with EGFR status assessed centrally by
IHC, 69 % (34/49) were IHC 0, 8 % (4/49) 1 ? , 20 %
(10/49) 2 ? and 2 % (1/49) 3 ?; thus, the majority of
subjects had tumors that were EGFR negative.
For exploratory purposes, subgroup analysis was per-
formed in terms of the HER2 status evaluated in the central
laboratory (Table 6). In terms of HER2 status evaluated by
IHC and FISH, as expected, ORR and CBR were higher in
the HER2-positive subgroup, althougha small number of
subjects had IHC or FISH negative tumors.
ORR was similar in EGFR IHC 0 and 2 ? subgroups;
there was a possible trend of a correlation between EGFR
status and tumor response; however, inference testing was
not performed. There was no significant difference in TTP
between EGFR-negative (IHC 0) and -positive (IHC 1 ? ,
2 ? , 3 ?) subgroups (p = 0.8025).
Baseline serum HER2 ECD concentration levels (col-
lected prior to this study treatment) were available for all
subjects. At screening, the majority of subjects had HER2
ECD levels [ 15 ng/ml (63 %). This finding may be
reflective of the advanced disease stage and overall tumor
burden of the population [11]. Exploratory analysis showed
no significant difference in TTP between two HER2 ECD
subgroups and no significant difference in HER2 ECD levels
between the no clinical benefit group and clinical benefit
group (p = 0.1539 and 0.3338, respectively) (Fig. 2a, b).
Discussion
In this study, lapatinib in combination with capecitabine
was well tolerated in Japanese patients with HER2-positive
MBC who had been treated with prior anthracyclines,
Table 4 Summary of tumor response in the ITT population
Best response, n (%)
CR 0
PR 12 (24)
SD, C 24 weeks 18 (35)
SD, \ 24 weeks 14 (27)
PD 6 (12)
NE 1 (2)
ORR 24 % (95 %CI 12.8, 37.5)
CBR 59 % (95 %CI 44.2, 72.4)
CR complete response, PR partial response, SD stable disease, PD
progressive disease, NE not evaluable, ORR overall response rate,
CBR clinical benefit rate (CR; PR; SD C 24 weeks)
Fig. 1 Kaplan-Meier estimates for the time to progression as
assessed at the Independent Review Facility
Table 5 Distribution of HER2 and EGFR biomarker results





FISH HER2 amplification, n (%) (n = 47)
Positive (C 2.0) 43 (91)
Borderline (1.8 to \ 2.0) 0
Negative (\ 1.8) 4 (9)





HER2 eligibility was determined at the local laboratory. One subject
was non-evaluable for HER2 and EGFR
HER2 human epidermal growth factor receptor 2, IHC immunohis-
tochemistry, FISH fluorescence in situ hybridization, EGFR epider-
mal growth factor receptor
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taxanes and trastuzumab. The safety results from 51 Jap-
anese subjects indicated adverse events were manageable
and consistent with the safety profile previously reported
[3, 4].
A phase I study, conducted outside of Japan, investi-
gated the drug-drug interaction between capecitabine and
lapatinib [6]. The results suggested there were no signifi-
cant changes in the PK of lapatinib, capecitabine and its
metabolites, 5-FU and FBAL. The 90 % confidence inter-
val for PK parameters, obtained from overseas study of 19
subjects, the AUC and Cmax of capecitabine were 5.64,
7.98 and 4.31, 7.98, respectively, whereas those of FBAL
were 16.3, 25.5 and 3.38, 4.65. The capecitabine intervals
were lower, whereas the FBAL intervals were higher in
Japanese subjects compared with foreign subjects. How-
ever, no differences were found (overlapping of confidence
intervals) in the AUC and Cmax of another capecitabine
metabolite, 5-FU (90 % CI 0.520, 0.772), and of lapatinib
(90 % CI 32.7, 63.2). Furthermore, the median tmax for
lapatinib, capecitabine, 5-FU and FBAL was similar
between Japanese and foreign subjects. These findings
suggest there are no clinically significant differences
between the two populations.
The pivotal overseas study reported that lapatinib in
combination with capecitabine would be a recommended
treatment option for patients with HER2-positive MBC
who had been previously treated with therapy including
trastuzumab [3, 4]. In this study report, the median TTP in
Japanese subjects was 36.0 weeks (95 %CI 27.1, 48.0),
which is comparable to overseas results (27.1 weeks). The
comparisons of TTP indicate a consistency between the
two study populations without the possibility of an ethnic
difference.
The tumor response rate in this study (24 %) also indi-
cated consistency with overseas studies (24 %). In contrast,
CBR in this study (59 %) was higher than that in overseas
studies (29 %). The tumor response evaluations by the
independent review were conducted in the same indepen-
dent facility for both studies; therefore, practical bias can
be excluded. The higher CBR compared with the overseas
study is considered to be related with the higher frequency
of the patients who have achieved C 24 weeks SD. This
finding is consistent with the results from another report by
Toi et al. [12] that reported a higher CBR in a Japanese
population treated with lapatinib monotherapy. By making
comparisons with the previously reported overseas study,
there were no clear differences in tumor profiles at baseline
such as HER2 status or adverse events observed during
treatment, except the discrepancy in hormone receptor
status, which was observed in the patient’s background
(ER- and PgR- rate; overseas study 48 % vs. this study
69 %). This study has limitations in providing details for
explaining how this discrepancy can be reasoned. One of
the possibilities is, as previously reported, that breast
cancer is a heterogeneous disease, and, in particular,
HER2-positive breast cancer is known to have variable
biological features based upon gene expression profiling,
such as luminal HER2? tumors, HER2-enriched and basal
HER2? tumors [13–17].
From this study on lapatinib and capecitabine given in a
Japanese population, a correlation between the HER2 IHC
score and tumor response has been suggested. This finding
is similar to that reported by Toi et al. [12]. No clear
correlation was observed between EGFR expression and
tumor response; this finding is consistent with that previ-
ously reported by Finn et al., suggesting no correlation with
EGFR expression and a benefit from lapatinib with pac-
litaxel [18]. There was no significant difference in TTP and
CBR observed between the two HER2 ECD subgroups.
However, no suggestion can be derived from this finding as
the study population was too small.
The efficacy and safety outcome of this study were
consistent with previous reports on lapatinib in combina-
tion with capecitabine. These findings confirm that this
regimen offers a clinically beneficial therapeutic option for
HER2-positive breast cancer patients in Japan.
Most recently, the results from clinical trials of the new
HER2-targeting agents pertuzumab and trastuzumab
Table 6 Subgroup analysis of centrally evaluated EGFR/HER2 status
EGFR IHC IHC 0 (n = 34) IHC 1 ? (n = 4) IHC 2 ? (n = 10) IHC 3 ? (n = 1)
ORR (%) (95 % CI) 29 (14, 44) 0 20 (0, 45) 0
HER2 IHC IHC 0 (n = 2) IHC 1 ? (n = 2) IHC 2 ? (n = 16) IHC 3 ? (n = 30)
ORR (%) (95 % CI) 0 0 13 (2, 38) 33 (17, 53)
HER2 FISH FISH negative (n = 4) FISH positive (n = 43)
ORR (%) (95 % CI) 0 28 (15, 44)
EGFR epidermal growth factor receptor, FISH fluorescence in situ hybridization, HER2 human epidermal growth factor receptor 2, IHC
immunohistochemistry, ORR overall response rate (CR; PR)
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emtansine have been reported, and these agents can be
considered as options in the HER2-positive breast cancer
treatment algorithm [19, 20]. As stated in this and previous
reports, the lapatinib and capecitabine combination shows
anti-tumor efficacy even in patients who have undergone
heavy treatment. Thus, lapatinib and capecitabine should
still be options for long-term treatment of breast cancer. In
order to maximize the treatment options for HER2-positive
breast cancer patients, the suitable clinical position of the
lapatinib and capecitabine combination needs to be clari-
fied by further evaluations including biomarkers.
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